SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare reports 11% rise in Q4 consolidated net profit

16 May 2016 Evaluate

Cadila Healthcare has reported results for the fourth quarter and year ended March 31, 2016.

The company has posted a fall of 2.59% in its net profit at Rs 338 crore for the quarter ended March 31, 2016 as compared to Rs 347 crore for the same quarter in the previous year. However, total income of the company has increased by 1.28% at Rs 1487.6 crore for quarter under review as compared to Rs 1468.8 crore for the quarter ended March 31, 2015.

On consolidated basis, the company has posted a rise of 10.93% in its net profit after taxes, minority interest and share of profit of associates at Rs 388.7 crore for the quarter ended March 31, 2016 as compared to Rs 350.4 crore for the corresponding quarter in the FY15. Total income of the company increased by 7.13% at Rs 2473.2 crore for quarter under review as compared to Rs 2308.7 crore for the same quarter ended previous year.

For the year ended March 31, 2016, the company has posted a rise of 55.56% in its net profit at Rs 1977.3 crore as compared to Rs 1271.1 crore for the same period in the previous year. Total income of company increased 31.08% at Rs 7169.4 crore for year under review as compared to Rs 5469.6 crore for the period ended March 31, 2015. 

For the year ended March 31, 2016, on the consolidated basis, the company has posted a rise of 32.33% in its net profit after taxes, minority interest and share of profit of associates at Rs 1522.6 crore as compared to Rs 1150.6 crore for the same period in the previous year. Total income of company has increased by 14.07% at Rs 9931.7 crore for year under review as compared to Rs 8706.7 crore for the period ended March 31, 2015.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×